GLP-1 Contraindications: Who Should Not Take Them
GLP-1 medications are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2, and require caution in pancreatitis, pregnancy, and certain GI conditions. A clinician screens for these before prescribing.
- Contraindicated with personal/family history of medullary thyroid carcinoma or MEN 2.
- Caution with history of pancreatitis, severe GI disease, and gallbladder disease.
- Not recommended in pregnancy; discontinue if planning pregnancy.
- A licensed clinician must screen for these before prescribing.
The boxed warning
Semaglutide and tirzepatide carry a boxed warning — the FDA's strongest — regarding thyroid C-cell tumors, based on rodent studies. They are contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).
Whether the rodent finding translates to humans is not established, but the contraindication is firm: these drugs should not be used by people with that personal or family history.
This is the first thing a clinician screens for, and it is non-negotiable.
Pancreatitis and GI conditions
A history of pancreatitis warrants caution. GLP-1 medications have been associated with pancreatitis in some reports, and while causation is debated, a prior episode raises the stakes. Clinicians weigh this carefully.
Severe gastrointestinal disease, including gastroparesis (delayed stomach emptying), is another area of caution, because GLP-1s slow gastric emptying and can worsen symptoms.
Gallbladder disease is also relevant, since rapid weight loss of any kind increases gallstone risk.
| Condition | Status |
|---|---|
| MTC or MEN 2 history | Contraindicated |
| Prior pancreatitis | Caution |
| Gastroparesis / severe GI | Caution |
| Pregnancy | Not recommended |
Pregnancy and other situations
GLP-1 medications are not recommended during pregnancy, and manufacturers advise discontinuing them before a planned pregnancy — typically two months before for semaglutide, given its long half-life. Weight loss is not a goal during pregnancy.
They are also not established for use in children below approved ages, and require dose caution in certain kidney or liver conditions.
People taking other medications, especially insulin or sulfonylureas, need monitoring because of hypoglycemia risk in combination.
How screening works
Before prescribing, a legitimate provider reviews your personal and family medical history, current medications, and relevant conditions. This is why a real prescription pathway with clinician evaluation is essential, and why 'no prescription needed' offers are a red flag.
The screening is not a formality: the contraindications above are the reason a licensed clinician, not a website, decides whether a GLP-1 is appropriate for you.
If a program does not ask about thyroid cancer history, pancreatitis, or pregnancy, that is a serious warning sign about the quality of its clinical process.
| Red flag | Why it's dangerous |
|---|---|
| No prescription required | Skips contraindication screening |
| No history questions | May miss MTC/pancreatitis risk |
The bottom line
GLP-1 medications are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2, and require caution in pancreatitis, severe GI disease, gallbladder disease, and pregnancy.
A licensed clinician must screen for these before prescribing. This screening is a core reason GLP-1 access requires a real evaluation, not a checkbox.
This is educational information, not medical advice; disclose your full history to your clinician.
Frequently asked questions
Who should not take GLP-1 medications?
People with a personal or family history of medullary thyroid carcinoma or MEN 2 should not take them. Caution applies with pancreatitis, severe GI disease, and pregnancy.
Are GLP-1s safe in pregnancy?
They are not recommended in pregnancy. Manufacturers advise stopping before a planned pregnancy, often two months before for semaglutide.
Why is clinician screening essential?
Because the contraindications require reviewing your personal and family history. 'No prescription needed' offers skip this and are a red flag.
Does prior pancreatitis rule out GLP-1s?
It warrants caution and a careful clinical discussion, not an automatic yes or no. Your clinician weighs the risk.
Sources
- FDA — drug labels and compounding status (Drugs@FDA, fda.gov/drugs/human-drug-compounding).
- NEJM — STEP, SELECT, SURMOUNT, SURPASS, SUSTAIN, PIONEER, FLOW trial publications.
- ClinicalTrials.gov registrations and prescribing information.
- Evidence policy and ledger: evidence policy.
The numbers behind this page
Checking the figures in this entry
Every price quoted in this entry comes from the programme's own pricing page and carries the date it was captured. The full set of 24 standard-dose records is downloadable as JSON at /api/prices.json, with molecule and dose class stated on every record. Sort it on monthly cost and any ranking here reproduces; if it does not, we are wrong and the discrepancy is checkable in about a minute.
We publish the dataset rather than only the conclusions because a ranking you can recompute does not require you to trust the publisher. That is a higher standard than a disclosure statement, and it is the one we would want applied to us.
Reading the price against the market
Where this sits in the market
The figures in this entry sit inside a market with a measurable shape, and that shape is what makes any single price readable.
12 programmes publish a price for both molecules. Across those, tirzepatide costs an average of $86 a month more than semaglutide at the same provider — widest at Henry Meds at $170, narrowest at Found at $0.
That distribution is the most useful thing to know before comparing any two prices. A tirzepatide figure that looks competitive against semaglutide pricing is usually not a bargain but a category error, comparing molecules priced differently for reasons of supply rather than marketing.
Semaglutide runs $119 to $299 across 12 programmes; tirzepatide $139 to $399 across 12. Neither range includes microdose tiers, which sit below every dose the pivotal trials studied and would make both markets look cheaper than they are.
Where this sits in the market
The figures in this entry sit inside a market with a measurable shape, and that shape is what makes any single price readable.
12 programmes publish a price for both molecules. Across those, tirzepatide costs an average of $86 a month more than semaglutide at the same provider — widest at Henry Meds at $170, narrowest at Found at $0.
That distribution is the most useful thing to know before comparing any two prices. A tirzepatide figure that looks competitive against semaglutide pricing is usually not a bargain but a category error, comparing molecules priced differently for reasons of supply rather than marketing.
Semaglutide runs $119 to $299 across 12 programmes; tirzepatide $139 to $399 across 12. Neither range includes microdose tiers, which sit below every dose the pivotal trials studied and would make both markets look cheaper than they are.
Questions this page answers
Where do these prices come from?
Each is read from the programme's own published pricing page and carries its capture date. The full set of 24 standard-dose records is at /api/prices.json with molecule and dose class on every record.
What is the cheapest verified GLP-1 programme?
NexLife at $119 a month for semaglutide and $139 for tirzepatide on its 12-month plan, both at standard therapeutic dosing and first-party verified September 4, 2026. Month-to-month, NexLife is $139 and $169; Oak Longevity ($133, flat, no membership) is the next-cheapest semaglutide programme.
Are compounded GLP-1 medicines FDA-approved?
No. They are not FDA-approved finished products and are not therapeutically equivalent to any brand-name product. FDA does not review them for safety, effectiveness or manufacturing quality before marketing.
Why do the same programmes quote two different prices?
Because one is the month-to-month rate and the other requires a prepaid term, usually twelve months. We rank on the month-to-month figure and state the prepaid rate separately, since a rate requiring a year's commitment is not the same offer.